Zydus Pharmaceuticals Initiates Nationwide Recall of Esomeprazole Magnesium Due to NDC Labeling Error
Zydus Pharmaceuticals (USA) Inc. has initiated a Class III nationwide recall of 4404 packs of Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mg. The recall, D-0102-2025, stems from an incorrect NDC number on product labeling. This event signals a quality control lapse, requiring immediate action from procurement and regulatory teams to assess inventory and ensure compliance across the USA.
FDA Action: Zydus Pharmaceuticals Recalls Esomeprazole Magnesium for Labeling Discrepancy
Zydus Pharmaceuticals (USA) Inc., based in Pennington, NJ, has initiated a voluntary Class III recall, designated D-0102-2025, for its Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mg. This action, commenced on November 14, 2024, and classified by the FDA on December 4, 2024, targets 4404 packs of lot M408002, with an expiration date of May 31, 2026. The primary reason for this recall is a labeling error: specifically, the use of an incorrect National Drug Code (NDC) number, 68382-849-94, on the product packaging. While a Class III recall indicates that the product is unlikely to cause adverse health consequences, it highlights a critical lapse in quality control and regulatory compliance. For procurement directors and regulatory affairs heads, this means an immediate need to verify existing stock of this specific lot. Failure to identify and quarantine affected products could lead to downstream compliance issues and potential disruptions in patient care, despite the low direct health risk. Supply chain VPs must ensure their distribution networks are promptly informed and that return procedures are efficiently managed across the USA nationwide distribution pattern.
Product and Manufacturing Profile: Esomeprazole Magnesium Supply Chain
The recalled product, Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mg, is a widely prescribed proton pump inhibitor (PPI) used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. The active pharmaceutical ingredient (API) is Esomeprazole Magnesium Dihydrate, a critical molecule in the global pharmaceutical market. This particular product is manufactured by Zydus Lifesciences Ltd. in Ahmedabad, India, and subsequently distributed in the United States by Zydus Pharmaceuticals (USA) Inc. The recall of 4404 packs, though a specific lot (M408002), represents a tangible disruption for entities relying on this particular supplier for their Esomeprazole Magnesium requirements. Business development executives should note that even minor labeling discrepancies can impact brand reputation and market confidence, especially for generic products where competition is high. Procurement teams must understand the full manufacturing and distribution chain for their critical generics, ensuring that quality control extends beyond the final distributor to the manufacturing site in India, where the initial packaging and labeling processes would have occurred.
Supply Chain Exposure: Implications for Esomeprazole Magnesium Buyers
The nationwide distribution of the affected Esomeprazole Magnesium lot (M408002) means that pharmaceutical wholesalers, pharmacies, and healthcare systems across the entire USA are potentially exposed to this labeling error. Procurement directors must initiate an immediate audit of their inventory to identify and segregate any packs bearing the incorrect NDC 68382-849-94. This is not merely a logistical exercise; it is a regulatory imperative to prevent the further distribution of mislabeled products. Regulatory affairs heads should guide their organizations on the proper handling and return procedures, ensuring compliance with FDA guidelines for Class III recalls. While the immediate health risk is low, the administrative burden and potential for supply chain friction are significant. Supply chain VPs need to assess their contractual agreements with Zydus Pharmaceuticals (USA) Inc. regarding recall management and ensure that the costs associated with reverse logistics and inventory adjustments are clearly defined. This event underscores the necessity of robust incoming quality inspection protocols, even for established suppliers and generic products, to catch such discrepancies before they impact the downstream supply chain and patient access.
Navigating Alternative Sourcing for PPIs Amidst Supply Disruptions
Given the recall, procurement teams reliant on Zydus Pharmaceuticals (USA) Inc. for Esomeprazole Magnesium should proactively review their alternative sourcing strategies for this essential proton pump inhibitor. While the current recall is Class III, it serves as a critical reminder of the fragility of single-source reliance. Identifying and qualifying alternative suppliers for Esomeprazole Magnesium, both finished dosage forms and potentially API, is paramount. This process involves rigorous due diligence, including facility audits, review of regulatory dossiers, and analytical testing to ensure product equivalence and consistent quality. Geographic diversity in the supplier base can mitigate risks associated with localized manufacturing issues or regional regulatory actions. For formulators, understanding the API source and its regulatory standing is as crucial as the finished product manufacturer. Business development executives should explore partnerships with manufacturers demonstrating strong quality systems and a clear regulatory compliance history. Proactive engagement with multiple FDA-approved manufacturers of Esomeprazole Magnesium can significantly reduce the impact of future supply chain disruptions, ensuring continuity of supply for this high-demand therapeutic agent.
Remediation and Future Compliance Outlook for Zydus Pharmaceuticals
The ongoing recall requires Zydus Pharmaceuticals (USA) Inc. to implement comprehensive corrective and preventive actions (CAPA) to address the root cause of the incorrect NDC labeling. This includes a thorough investigation into the labeling process at the manufacturing facility, Zydus Lifesciences Ltd. in Ahmedabad, India, and the subsequent distribution verification. The FDA will closely monitor the effectiveness of these CAPA measures and the overall recall execution. For regulatory affairs heads, this event underscores the importance of continuous vigilance over supplier quality systems. While a Class III recall typically does not lead to immediate severe regulatory sanctions like an Import Alert, repeated quality system failures, even minor ones, can escalate FDA scrutiny. Such an escalation could result in Warning Letters, 483 observations during inspections, or even more stringent actions affecting the manufacturing site in India. Business development executives should consider the potential for reputational damage and the impact on future contract negotiations. Maintaining a robust quality management system is critical for Zydus to restore confidence among its distributors and customers and to avoid more significant commercial and regulatory repercussions in the future.